Shortly after reports of blood clots post-vaccination, several countries temporarily suspended the Covishield vaccine. However, an interim analysis involving 32,459 participants reported the vaccine to be 79% effective against symptomatic COVID-19 and 100% effective at preventing critical disease and hospitalization. Assessing the safety and efficacy The study included roughly 20% of patients above the age of 65; the vaccine was 80% effective in this age group.
Held across Argentina, Chile, Colombia, France, Peru, and the US, in 88 trial centers, the study has proven the vaccine's efficacy to be consistent across ethnicity and age. To address the issue regarding blood clots post-vaccination, the Data Safety Monitoring Board (DSMB) conducted a specific review. The thrombotic event and cerebral venous sinus thrombosis (CVST) were analyzed among 21,538 participants receiving at least the…
